74 results on '"Parving, H.-H."'
Search Results
2. The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers
3. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1
4. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
5. Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
6. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
7. A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus
8. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes
9. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial
10. P11.03 PULSE PRESSURE PARTIALLY EXPLAINS THE INCREASED INCIDENT CARDIOVASCULAR DISEASE ASSOCIATED WITH INFLAMMATION IN TYPE 1 DIABETES: A 12-YR FOLLOW-UP STUDY
11. Telomere length predicts all-cause mortality in patients with type 1 diabetes
12. 6.1 LOW-GRADE INFLAMMATION AND ENDOTHELIAL DYSFUNCTION PRECEDE THE INCREASE IN PULSE PRESSURE IN TYPE 1 DIABETES:A 20-YEAR LONGITUDINAL STUDY
13. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial
14. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
15. Long-term prevention of diabetic nephropathy: an audit
16. Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control
17. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
18. Anaemia in diabetes: is there a rationale to TREAT?
19. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
20. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications
21. The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy
22. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
23. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy
24. Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
25. Total plasma homocysteine is associated with hypertension in Type I diabetic patients
26. Controlling hypertension in diabetes
27. Pregnancy and progression of diabetic nephropathy
28. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients
29. Changes in renal function during weight loss induced by high vs low-protein low-fat diets in overweight subjects
30. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy
31. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment
32. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy
33. Glomerular hyperfiltration in microalbuminuric NIDDM patients
34. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
35. Insertion/deletion polymorphism in the angiotensin-l-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy
36. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen
37. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen
38. Monitoring kidney function in diabetic nephropathy
39. Monitoring kidney function in diabetic nephropathy
40. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
41. Glomerular size-and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
42. Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients
43. The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
44. Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy
45. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
46. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients
47. Lack of familial predisposition to cardiovascular disease in Type 1 (insulin-dependent) diabetic patients with nephropathy
48. Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy
49. Diabetic nephropathy and arterial hypertension
50. Effects of insulin on kidney function and sodium excretion in healthy subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.